12 results about "Pharmasolve" patented technology

A bremelanotide pharmaceutical composition, a formulation thereof, a preparation method therefor, and use thereof. The bremelanotide pharmaceutical composition comprises bremelanotide as a pharmaceutically active ingredient, a solvent, and a polymer. The solvent includes one or more of N-methylpyrrolidone, polyethylene glycol, dimethyl sulfoxide, and benzyl benzoate and enables the plasma concentration of bremelanotide to be stably greater than 0.1 ng / mL at 120-168 h, thereby achieving the target sustained release. The bremelanotide pharmaceutical composition can be directly injected and does not require the addition of a thickener, a gel-forming agent, or other excipients.

This invention discloses a method for determining the encapsulation efficiency of amphotericin B liposomes for injection, comprising the following steps: separating the amphotericin B liposome solution for injection using solid-phase extraction adsorption to obtain an encapsulated drug solution and a free drug solution; and determining the drug mass concentration C in the encapsulated drug solution using HPLC. 包封 Drug mass concentration C in free drug solution 游离 And the total drug concentration C in the amphotericin B liposome solution before separation 总 The encapsulation efficiency and recovery rate of amphotericin B liposomes were calculated. This invention utilizes a macroporous copolymer of divinylbenzene and N-vinylpyrrolidone as the adsorbent in a solid-phase extraction adsorption method. Its macroporous structure provides ample adsorption sites while avoiding physical compression and damage to the liposome vesicles. This method achieves the separation of free amphotericin B liposomes from the encapsulated drug, exhibiting good reproducibility, high accuracy, simple operation, and high recovery rate.

The invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, an oily phase and at least a) a phenyl silicone oil of formula (I) [Chem 1] (I) wherein—Me is methyl and Ph is phenyl, OR′ represents an —OSiMe3 group, —y ranges from 1 to 1000, and—z ranges from 1 to 1000, b) a C8-C30 fatty alcohol, c) a branched dextrin ester, and d) advantageously a liposoluble polymer selected from among the group consisting of: (i) acrylate polymers selected from among the group consisting of silicone acrylate polymers, acrylate polymers comprising an alkyl chain of at least 10 carbon atoms, and copolymers of acrylates and acrylamide, (ii) copolymers of vinylpyrrolidone (VP) and alkene comprising at least 18 carbon atoms, and (iii) mixtures thereof, and its use in particular on the lips for a make-up result with improved gloss and longer-lasting gloss and color. Preferably, the composition is in a semi-solid or solid form.

The present invention belongs to the field of biopharmaceuticals and provides a κ-opioid receptor agonist having the following formula, its stereoisomers, and pharmaceutically acceptable salts thereof. The κ-opioid receptor agonist has high selectivity for the κ-opioid receptor, its activity is 3 to 15 times that of diferikephalin, and has high pharmacological activity, and can be used for the treatment, prevention and / or remission of pruritus, and / or analgesia. D-Phe-AA1-AA2-D-Lys-4-aminopiperidine-4-carboxamide-AA3-AA4-AA5 [Formula I].

The invention relates to the technical field of pharmaceutical preparations, and particularly provides a brexpiprazole sustained-release injection based on in-situ phase change gel as well as a preparation method and application of the brexpiprazole sustained-release injection. The brexpiprazole sustained-release injection is prepared from brexpiprazole, N-methyl pyrrolidone and a polylactic acid-glycolic acid copolymer according to the weight ratio of (0.1 to 0.2): (3 to 3.8): 1, wherein the intrinsic viscosity of the polylactic acid-glycolic acid copolymer is (0.1 to 0.3) dL / g. The preparation process of the brexpiprazole sustained-release injection is relatively simple and convenient, and the brexpiprazole sustained-release injection is a homogeneous solution before injection, so that the injection tolerance of a patient is effectively improved; the inherent problems that brexpiprazole is extremely high in hydrophobicity, rapid in-vivo elimination and free of remarkable central activity of metabolites are solved, stable slow release of blood concentration for several weeks is achieved, the drug release kinetics is highly predictable and good in reproducibility, and the purposes of reducing the drug administration frequency and improving the patient compliance are achieved.

The present invention belongs to the technical field of medicine. Disclosed are a microneedle composition containing semaglutide, and a preparation method therefor and the use thereof. The microneedle composition containing semaglutide consists of a needle body and a substrate, wherein the components of the needle body comprise semaglutide, a cosolvent, and an excipient; the cosolvent is selected from one or more of Tween, Span, propylene glycol, glycerol, and lecithin; and the excipient is selected from one or more of dextran, polyvinylpyrrolidone, hyaluronic acid, and water-soluble cyclodextrin. A soluble microneedle is prepared from semaglutide and the microneedle excipient, which has sufficient mechanical strength to pierce the skin, thereby achieving transdermal delivery of a macromolecular polypeptide drug. Moreover, in a pharmacokinetic experiment, the microneedle composition can simultaneously achieve a maximum plasma concentration with an injection dosage form, and the relative bioavailability can be improved by 40-60 times compared with that of an oral dosage form. The microneedle composition is present in a solid form, thus significantly improving the stability of semaglutide and substantially reducing the cost requirements for storage.

Pharmaceutical formulations are provided that include a 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitor with improved solubility for oral administration. Also provided are pharmaceutical formulations that include a selective 12-LOX inhibitor amorphously dispersed in a material selected from vinylpyrrolidone-vinyl acetate copolymer (Kollidon VA64), aminomethyl acrylate copolymer (Eudragit EPO), hydroxypropyl methylcellulose E3 (HPMC E3), or a combination thereof, and have a high drug load of 30% or more, comprising 40-80% of the total solid content of the formulation. Alternatively, the formulations contain additives, such as surfactants (sodium lauryl sulfate), crystallization inhibitors, or pH adjusters, in an amount of up to 20% of the total solid content of the formulation.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a solid dispersion of acetosalis flavonoids, a solid dosage form, and a preparation method thereof. The raw materials for the solid dispersion include acetosalis flavonoids, a homopolymer of N-vinylpyrrolidone, and inulin, wherein the N-vinylpyrrolidone homopolymer is povidone K30. The acetosalis flavonoid solid dosage form of this invention achieves a cumulative dissolution rate of over 90% within 30 minutes; the preparation process is simple, does not use any organic solvents, and exhibits very rapid dissolution.

The present invention aims to provide an injectable pharmaceutical composition containing diferikephalin that can reduce human error and labor associated with dosage preparation in medical settings. [Solution] The present invention relates to an injectable pharmaceutical composition containing diferikephalin or a pharmacoagulably acceptable salt thereof for the treatment of pruritus in dialysis patients, wherein the injectable pharmaceutical composition is designed to reduce human error and labor associated with dosage preparation in medical settings, and the injectable pharmaceutical composition contains diferikephalin or a pharmacoagulably acceptable salt thereof in amounts of 17.5 μg, 25.0 μg, 35.0 μg, or 42.5 μg in free form equivalent, and relates to an injectable pharmaceutical composition for administration to dialysis patients with a dry weight of less than 45 kg, 45 kg or more but less than 65 kg, 65 kg or more but less than 85 kg, or 85 kg or more, respectively.

The invention discloses a novel long-acting preparation and a preparation method thereof, belongs to the field of pharmaceutical preparations, and finds that a certain amount of glyceryl monolinoleate (GMLO) and soybean lecithin (SPC) can be fully and uniformly mixed in a certain amount of ethanol (ETOH) or N-methyl pyrrolidone (NMP) to form a clear liquid with good fluidity, and the liquid has a good effect on hydrophobic drugs ZL006-05 (code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name Y-3, code name The compound has a good dissolving effect. The formula (1) is shown in the description. When the liquid preparation is exposed to a water-containing component such as body fluid, gel is formed, so that a long-acting drug release effect is achieved. The liquid preparation can also be used for slow-release carriers of drugs with other properties. The invention also relates to a delivery method using the liquid formulation.

The invention belongs to the technical field of cosmetics and skin medicine preparations, and particularly relates to a hydrogel composition containing elaeagnus conferta roxb, a preparation method of the hydrogel composition and a network pharmacology analysis and evaluation method. The composition is prepared from the following components: 1.5 to 2.5 percent w / v of sodium alginate, 0.5 to 1.5 percent w / v of hyaluronic acid, 4 to 6 percent w / v of glycerol, 0.2 to 0.3 percent w / v of ceramide, 0.4 to 0.6 percent w / v of glycyrrhizic acid, 0.05 to 0.15 percent w / v of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 0.2 to 0.3 percent w / v of sodium pyrrolidone carboxylate, 0.2 to 0.3 percent w / v of allantoin, 0.4 to 0.6 percent w / v of adenosine triphosphate and 0.5 to 5 percent w / v of elaeagnus conferta roxb extract. The invention systematically overcomes the technical resistance of unknown components, fuzzy mechanism, low dosage form efficiency and disjoint verification of the natural extract in the treatment of the specific dermatitis from the whole chain innovation of component analysis, mechanism verification, dosage form design and evaluation system.